THEMISMED · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 18/100 — Quality 28 · Valuation 1 · Momentum 25
| Share price | ₹113.21 |
| Market cap | ₹1,086 Cr |
| P/B ratio | 2.7 |
| ROE | 12.4% |
| ROCE | 2.9% |
| Dividend yield | 0.43% |
| Book value | ₹43.06 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹342 Cr | ₹1 Cr | 0.0% |
| 2025 | ₹406 Cr | ₹30 Cr | 12.0% |
| 2024 | ₹382 Cr | ₹44 Cr | 13.0% |
| 2023 | ₹354 Cr | ₹57 Cr | 19.0% |
| 2022 | ₹395 Cr | ₹73 Cr | 24.0% |
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, cal